CSL Limited Announces $1.5 Billion U.S. Expansion for Plasma Therapy Manufacturing
CSL Limited plans to invest $1.5 billion in the U.S. over five years to expand plasma therapy manufacturing, creating hundreds of jobs and strengthening the supply chain for critical medicines. This builds on a previous $3 billion investment since 2018, which created over 6,500 jobs. The expansion highlights CSL's commitment to patient care, job creation, and innovation in healthcare.
CSL Limited has announced plans to invest approximately $1.5 billion in the United States over the next five years to expand its manufacturing capabilities for plasma-derived therapies. This initiative is expected to generate hundreds of high-quality American jobs, strengthen the U.S. supply chain for critical medicines, and help meet the growing demand for immunoglobulin therapies. The investment builds on CSL’s previous $3 billion commitment to its U.S. operations since 2018, which has created more than 6,500 jobs across 44 states. The expansion underscores CSL’s ongoing commitment to patient care, job creation, and innovation in the healthcare sector. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
